Literature DB >> 22102703

BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas.

Qingguo Yan1, Yuanxue Huang, A James Watkins, Sylvia Kocialkowski, Naiyan Zeng, Rifat A Hamoudi, Peter G Isaacson, Laurence de Leval, Andrew Wotherspoon, Ming-Qing Du.   

Abstract

The genetics and pathogenesis of splenic marginal zone lymphoma are poorly understood. The lymphoma lacks chromosome translocation, and approximately 30% of cases are featured by 7q deletion, but the gene targeted by the deletion is unknown. A recent study showed inactivation of A20, a "global" NF-κB negative regulator, in 1 of 12 splenic marginal zone lymphomas. To investigate further whether deregulation of the NF-κB pathway plays a role in the pathogenesis of splenic marginal zone lymphoma, we screened several NF-κB regulators for genetic changes by PCR and sequencing. Somatic mutations were found in A20 (6/46=13%), MYD88 (6/46=13%), CARD11 (3/34=8.8%), but not in CD79A, CD79B and ABIN1. Interestingly, these genetic changes are largely mutually exclusive from each other and MYD88 mutation was also mutually exclusive from 7q deletion. These results strongly suggest that deregulation of the TLR (toll like receptor) and BCR (B-cell receptor) signaling pathway may play an important role in the pathogenesis of splenic marginal zone lymphoma.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102703      PMCID: PMC3347666          DOI: 10.3324/haematol.2011.054080

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  19 in total

1.  Oncogenic CARD11 mutations in human diffuse large B cell lymphoma.

Authors:  Georg Lenz; R Eric Davis; Vu N Ngo; Lloyd Lam; Thaddeus C George; George W Wright; Sandeep S Dave; Hong Zhao; Weihong Xu; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Wing C Chan; Louis M Staudt
Journal:  Science       Date:  2008-03-06       Impact factor: 47.728

2.  The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.

Authors:  Urban Novak; Andrea Rinaldi; Ivo Kwee; Subhadra V Nandula; Paola M V Rancoita; Mara Compagno; Michaela Cerri; Davide Rossi; Vundavalli V Murty; Emanuele Zucca; Gianluca Gaidano; Riccardo Dalla-Favera; Laura Pasqualucci; Govind Bhagat; Francesco Bertoni
Journal:  Blood       Date:  2009-03-03       Impact factor: 22.113

Review 3.  A20: central gatekeeper in inflammation and immunity.

Authors:  Beatrice Coornaert; Isabelle Carpentier; Rudi Beyaert
Journal:  J Biol Chem       Date:  2008-11-13       Impact factor: 5.157

4.  A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma.

Authors:  E Chanudet; Y Huang; K Ichimura; G Dong; R A Hamoudi; J Radford; A C Wotherspoon; P G Isaacson; J Ferry; M-Q Du
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

5.  The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses.

Authors:  David L Boone; Emre E Turer; Eric G Lee; Regina-Celeste Ahmad; Matthew T Wheeler; Colleen Tsui; Paula Hurley; Marcia Chien; Sophia Chai; Osamu Hitotsumatsu; Elizabeth McNally; Cecile Pickart; Averil Ma
Journal:  Nat Immunol       Date:  2004-08-29       Impact factor: 25.606

6.  Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma.

Authors:  R Eric Davis; Vu N Ngo; Georg Lenz; Pavel Tolar; Ryan M Young; Paul B Romesser; Holger Kohlhammer; Laurence Lamy; Hong Zhao; Yandan Yang; Weihong Xu; Arthur L Shaffer; George Wright; Wenming Xiao; John Powell; Jian-Kang Jiang; Craig J Thomas; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Randy D Gascoyne; Joseph M Connors; Nathalie A Johnson; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Wyndham H Wilson; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Dennis D Weisenburger; Wing C Chan; Susan K Pierce; Louis M Staudt
Journal:  Nature       Date:  2010-01-07       Impact factor: 49.962

Review 7.  The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology.

Authors:  Lars Vereecke; Rudi Beyaert; Geert van Loo
Journal:  Trends Immunol       Date:  2009-07-28       Impact factor: 16.687

8.  Frequent inactivation of A20 in B-cell lymphomas.

Authors:  Motohiro Kato; Masashi Sanada; Itaru Kato; Yasuharu Sato; Junko Takita; Kengo Takeuchi; Akira Niwa; Yuyan Chen; Kumi Nakazaki; Junko Nomoto; Yoshitaka Asakura; Satsuki Muto; Azusa Tamura; Mitsuru Iio; Yoshiki Akatsuka; Yasuhide Hayashi; Hiraku Mori; Takashi Igarashi; Mineo Kurokawa; Shigeru Chiba; Shigeo Mori; Yuichi Ishikawa; Koji Okamoto; Kensei Tobinai; Hitoshi Nakagama; Tatsutoshi Nakahata; Tadashi Yoshino; Yukio Kobayashi; Seishi Ogawa
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

9.  Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Authors:  Mara Compagno; Wei Keat Lim; Adina Grunn; Subhadra V Nandula; Manisha Brahmachary; Qiong Shen; Francesco Bertoni; Maurilio Ponzoni; Marta Scandurra; Andrea Califano; Govind Bhagat; Amy Chadburn; Riccardo Dalla-Favera; Laura Pasqualucci
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

10.  TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma.

Authors:  Roland Schmitz; Martin-Leo Hansmann; Verena Bohle; Jose Ignacio Martin-Subero; Sylvia Hartmann; Gunhild Mechtersheimer; Wolfram Klapper; Inga Vater; Maciej Giefing; Stefan Gesk; Jens Stanelle; Reiner Siebert; Ralf Küppers
Journal:  J Exp Med       Date:  2009-04-20       Impact factor: 14.307

View more
  44 in total

1.  Nuclear factor-κB dysregulation in splenic marginal zone lymphoma: new therapeutic opportunities.

Authors:  Luca Arcaini; Davide Rossi
Journal:  Haematologica       Date:  2012-05       Impact factor: 9.941

Review 2.  Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors:  Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Expert Opin Investig Drugs       Date:  2018-06-07       Impact factor: 6.206

Review 3.  NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

Authors:  Li Yu; Ling Li; L Jeffrey Medeiros; Ken H Young
Journal:  Blood Rev       Date:  2016-10-13       Impact factor: 8.250

Review 4.  Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?

Authors:  John C Allen; Fatima Talab; Joseph R Slupsky
Journal:  Int J Hematol Oncol       Date:  2016-05-26

5.  Toll-like receptor stimulation in splenic marginal zone lymphoma can modulate cell signaling, activation and proliferation.

Authors:  Eleonora Fonte; Andreas Agathangelidis; Daniele Reverberi; Stavroula Ntoufa; Lydia Scarfò; Pamela Ranghetti; Giovanna Cutrona; Alessandra Tedeschi; Aliki Xochelli; Federico Caligaris-Cappio; Maurilio Ponzoni; Chrysoula Belessi; Zadie Davis; Miguel A Piris; David Oscier; Paolo Ghia; Kostas Stamatopoulos; Marta Muzio
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

Review 6.  A20: linking a complex regulator of ubiquitylation to immunity and human disease.

Authors:  Averil Ma; Barbara A Malynn
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

Review 7.  Molecular pathogenesis of chronic lymphocytic leukemia.

Authors:  Gianluca Gaidano; Robin Foà; Riccardo Dalla-Favera
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 8.  New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.

Authors:  Robert C Rickert
Journal:  Nat Rev Immunol       Date:  2013-08       Impact factor: 53.106

Review 9.  Targeting pathological B cell receptor signalling in lymphoid malignancies.

Authors:  Ryan M Young; Louis M Staudt
Journal:  Nat Rev Drug Discov       Date:  2013-03       Impact factor: 84.694

Review 10.  Inhibitors of B-cell receptor signaling for patients with B-cell malignancies.

Authors:  Michael Y Choi; Thomas J Kipps
Journal:  Cancer J       Date:  2012 Sep-Oct       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.